XTALPI (02228) subsidiary AILUX announces strategic cooperation with Lilly to empower (AI-driven) dual-specific antibody development.

XTALPI (02228) announced that Shanghai Ailuxi Biological Technology Co., Ltd. (Ailux Shanghai), a wholly-owned subsidiary of the global leading company in AI drug discovery, XtalPi, has reached a platform-based strategic collaboration with Eli Lilly and Company (Lilly) to accelerate the discovery and development of bispecific antibodies for treating various diseases. Through the collaboration, Lilly will have access to Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis to design antibodies with innovative functions, superior efficacy, and ideal drug-like properties. Under the terms of the collaboration, Lilly may nominate target pairs for bispecific antibody design and obtain a license to use the Ailux patent platform for internal use. The collaboration includes upfront and near-term milestone payments (including platform license options) totaling tens of millions of dollars. The potential total value of the collaboration (including development, regulatory, and commercial milestones) could reach up to $345 million. Ailux Shanghai is an indirect wholly-owned subsidiary of Ailux Holdings Limited (Ailux Holdings), which is a subsidiary of XtalPi. Ailux Holdings is XtalPi's specialized biopharmaceutical innovation platform that uses AI-driven solutions to develop advanced biologics. As XtalPi's dedicated biopharmaceutical platform, Ailux combines proprietary computational models with cutting-edge wet lab capabilities to target traditionally undruggable targets and design biologics with innovative drug potential. Ailux's global team of over 100 people collaborates with top biopharmaceutical companies to transform the latest science into transformative drugs.